Cargando...
Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells
PD0332991 (palbociclib/Ibrance(®)) is a cyclin-dependent kinase (CDK)4/6 inhibitor that has recently been approved for the treatment of estrogen receptor-positive advanced breast cancer. The present study investigated the antiproliferative effects of PD0332991 on gastric cancer (GC) cells and the un...
Gardado en:
| Publicado en: | Int J Mol Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5846637/ https://ncbi.nlm.nih.gov/pubmed/29436583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijmm.2018.3460 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|